Key Highlights

  • Actuate's randomized Phase 2 trial (Actuate-1801 Part 3B) showed elraglusib plus chemotherapy extended median overall survival to 10.1 months versus 7.2 months for chemotherapy alone in metastatic pancreatic cancer, a hazard ratio of 0.62 (p=0.02).
  • The FDA has granted elraglusib rare pediatric disease designation for Ewing sarcoma and orphan drug designation for soft tissue sarcomas; an early pediatric study showed responses in Ewing sarcoma and neuroblastoma.
  • As of March 31, 2026, Actuate held $8.1 million in cash and has told investors its funds will not cover operations beyond July 2026 without additional financing, a going-concern qualification.
  • Actuate-1801 Part 3B, a randomized Phase 2 trial, enrolled 286 previously untreated metastatic pancreatic cancer patients across 60 sites in six countries, randomizing 2:1 to elraglusib plus gemcitabine/nab-paclitaxel (GnP) or GnP alone.

Actuate Therapeutics, (NASDAQ:ACTU) a clinical-stage biopharmaceutical company built around the GSK-3β inhibitor elraglusib, reported statistically significant overall-survival data from a randomized Phase 2 pancreatic-cancer trial in January 2026 and is working to translate earlier pediatric-cancer signals in Ewing sarcoma and neuroblastoma into a registration-directed program, even as its cash position leaves little room for delay.

Why Actuate Therapeutics Is Back in Investors' Sights

Actuate Therapeutics, Inc. (ACTU) has spent 2026 trying to convert years of early-stage data on its lead drug, elraglusib, into a defined late-stage pathway. Its most concrete step came on January 12, 2026, when it disclosed updated results from a randomized Phase 2 study in metastatic pancreatic cancer, presented days earlier at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. At the same time, Actuate has been laying groundwork, rather than announcing a launch, for a further push into rare pediatric cancers.

Elraglusib and Actuate's GSK-3β Platform

Based in Fort Worth, Texas, Actuate is a clinical-stage biopharmaceutical company with a single investigational asset, elraglusib (formerly 9-ING-41), a small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). Per its SEC filings, elraglusib is designed to enter cancer cells and block GSK-3β, interfering with NF-κB signaling and DNA damage response pathways that tumors use to resist chemotherapy. Actuate also describes elraglusib as a potential mediator of anti-tumor immunity through regulation of immune checkpoints, including PD-1, PD-L1 and LAG-3. The company has tested the drug, alone and combined with chemotherapy, in more than 500 patients across solid tumors, per its May 2026 corporate presentation.

The Actuate-1801 Part 3B Survival Data Behind ACTU's Catalyst

Actuate-1801 Part 3B, a randomized Phase 2 trial, enrolled 286 previously untreated metastatic pancreatic cancer patients across 60 sites in six countries, randomizing 2:1 to elraglusib plus gemcitabine/nab-paclitaxel (GnP) or GnP alone. In its January 12, 2026 press release, filed with the SEC as an 8-K exhibit, Actuate said the trial met its primary endpoint: median overall survival of 10.1 months with elraglusib versus 7.2 months for chemotherapy alone, a hazard ratio of 0.62 (p=0.02), which the company characterized as a 38% reduction in the risk of death.

Twelve-month survival roughly doubled to 44.4% from 22.3%, and 24-month survival rose to 12.9% from 2.6%. As of the November 2025 data cut, 17 patients remained alive on elraglusib, including three past the two-year mark, versus none on GnP alone, according to CEO Daniel Schmitt. Serious treatment-related adverse events were similar between arms (56.1% versus 56.4%), with no new safety signals reported. Actuate has said it plans to meet the FDA and EMA in the first half of 2026 to discuss a Phase 3 registration study design.

Recent Financial and Operational Results

Actuate's Form 10-Q for the quarter ended March 31, 2026, filed May 14, 2026, shows a company still entirely dependent on external financing, with no product revenue. The filing reports cash and cash equivalents of $8,134,004 and working capital of $3,797,551 as of quarter-end. During the quarter, Actuate sold 198,793 shares under its at-the-market facility at a weighted-average price of $2.68 per share for net proceeds of $519,624, leaving roughly $99.5 million of remaining ATM capacity.

Funding History, Cash Position and the Going-Concern Question

Actuate went public on Nasdaq in August 2024, pricing its IPO at $8.00 per share for estimated net proceeds of approximately $19.2 million. Since then it has repeatedly returned to capital markets: a $50 million committed equity facility with B. Riley Principal Capital II in March 2025, a shelf registration in September 2025, and a new at-the-market agreement with B. Riley Securities and Craig-Hallum Capital Group in November 2025 for up to $100 million in stock. Despite this access to capital, the 10-Q states that management "anticipates... that our cash and cash equivalents on hand will not satisfy the Company's operational and capital requirements beyond July 2026 without raising additional capital," and concludes there is "substantial doubt regarding the Company's ability to continue as a going concern." That disclosure makes raising cash Actuate's most immediate priority.

Growth Opportunities: Oral Elraglusib and the Pediatric Pathway

Beyond pancreatic cancer, Actuate's strategy includes an oral elraglusib tablet, for which the FDA has cleared an IND to begin a Phase 1/2 study targeting colorectal cancer, non-small cell lung cancer and melanoma. Its pediatric effort centers on Ewing sarcoma and neuroblastoma. The Actuate-1902 Phase 1/2 study enrolled 40 patients ages 3 to 21 with relapsed or refractory cancers and closed its Phase 1 portion in July 2025; per Actuate's 2025 annual report, it produced two complete metabolic responses in Ewing sarcoma and one complete response in neuroblastoma, plus disease control in 10 of 19 patients on elraglusib with cyclophosphamide and topotecan.

Based on that signal, Actuate has named Ewing sarcoma and neuroblastoma priority indications and intends to pursue an international investigator consortium toward registration. The FDA granted elraglusib orphan drug designation for soft tissue sarcomas in July 2024 and rare pediatric disease designation for Ewing sarcoma in November 2024, positioning the company for a priority review voucher on approval, potentially worth $150-200 million if sold. This pediatric program remains in the planning and fundraising stage.

Material Risks Facing Actuate Therapeutics

Actuate's risks are unusually concentrated. It depends entirely on a single drug candidate, has no approved products or revenue, and its going-concern disclosure creates real risk of dilutive share issuance or delayed, reduced-scope programs if financing does not materialize on acceptable terms. The pediatric strategy is explicitly contingent on additional capital and on assembling an international investigator consortium, so timelines are not fully within the company's control. Clinical results to date, including the Actuate-1801 Part 3B data, are interim and subject to change with further follow-up; neither program has reached a completed pivotal trial or FDA submission. Actuate also competes with larger, better-capitalized oncology developers and depends on third parties to run its trials.

Outlook

In an upside scenario, Actuate secures near-term financing, advances the mPDAC survival data into an agreed Phase 3 design with regulators, and formalizes an international pediatric-cancer consortium. In a base case, the company funds operations incrementally through its at-the-market and equity facilities while data matures, with pediatric and oral-tablet programs progressing more slowly pending capital. In a downside scenario, Actuate cannot raise sufficient capital, forcing delays, reduced scope or termination of one or more programs, consistent with its own disclosed risk factors. This article offers no share-price forecast; investors should weigh the survival data against the going-concern disclosure.

Conclusion

Actuate Therapeutics, Inc. (ACTU) enters the second half of 2026 with a clinical achievement in its randomized pancreatic-cancer survival data and an early-stage rationale for pursuing rare pediatric cancers such as Ewing sarcoma and neuroblastoma. Whether ACTU can translate either program into registration will depend heavily on financing decisions the company itself calls urgent, making the coming months a test of both capital-raising execution and clinical science.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.